肌酐清除率可预测创伤性脑损伤患者的目标依诺肝素剂量
该回顾性研究纳入2017年8月至2020年2月一家城市学术型一级创伤中心收治的120例创伤性脑损伤患者(年龄>18岁、住院>48小时、头颈部AIS≥3),按达到目标抗Xa水平所需依诺肝素剂量分组,比较肌酐清除率与体重的相关性。结果显示,平均肌酐清除率随依诺肝素剂量增加而显著升高(Pearson相关系数0.484,P<0.001),入院体重也随剂量需求增加而升高(Pearson相关系数0.411,P<0.001)。作者认为肌酐清除率预测目标依诺肝素剂量优于基于体重的策略,但需更大样本研究验证肌酐清除率指导依诺肝素 dosing 的价值。
要点
- 在120例创伤性脑损伤患者中,达到目标抗Xa水平所需依诺肝素剂量与肌酐清除率相关(Pearson相关系数0.484,P<0.001),与入院体重也相关(Pearson相关系数0.411,P<0.001)。
- 作者认为肌酐清除率预测创伤性脑损伤患者目标依诺肝素剂量优于基于体重的策略。
- 研究期间发生深静脉血栓5例(4.2%)、肺栓塞0例、死亡5例(4.2%)。
- 作者指出需更大样本研究验证肌酐清除率数值用于指导依诺肝素给药。
- 证据等级为预后与流行病学Level IV。
适用人群与场景
- 年龄大于18岁、住院时间大于48小时、头颈部简明损伤定级(AIS)≥3的创伤性脑损伤患者,收治于城市学术型一级创伤中心。
- 排除:无创伤性脑损伤、接受除依诺肝素12小时给药方案以外的深静脉血栓预防、未检测抗Xa水平、未达到目标抗Xa水平的患者。
诊断标准与关键阈值
- 以达到目标抗Xa水平所需的依诺肝素剂量进行分组。
处置流程与药物剂量
- 近期指南推荐创伤性脑损伤患者起始依诺肝素30 mg每日两次,然后考虑基于体重的给药。
- 研究按依诺肝素12小时给药方案进行深静脉血栓预防,并以抗Xa水平达标为目标调整剂量。
研究设计与关键结果
- 回顾性研究纳入120例患者,平均年龄47岁,68%为男性,平均住院时间24天。
- 发生深静脉血栓5例(4.2%),肺栓塞0例,死亡5例(4.2%)。
- 平均肌酐清除率随依诺肝素剂量增加而显著升高,Pearson相关系数0.484(P<0.001)。
- 入院体重也随依诺肝素剂量需求增加而升高,Pearson相关系数0.411(P<0.001)。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:预后与流行病学Level IV。
- 局限:作者指出需更大样本研究验证肌酐清除率数值用于指导依诺肝素给药。
对床旁实践的改变
- 作者认为肌酐清除率预测创伤性脑损伤患者目标依诺肝素剂量优于基于体重的策略。
- 作者建议需进一步研究以验证肌酐清除率数值用于指导依诺肝素给药。
指南或共识出处
- 近期指南推荐创伤性脑损伤患者起始依诺肝素30 mg每日两次,然后考虑基于体重的给药(原文未注明指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with traumatic brain injury (TBI) are at high risk of venous thromboembolism (VTE). Recent guidelines recommend starting TBI patients on enoxaparin 30 mg twice daily and then considering weight-based dosing. Creatinine clearance may be better than weight for patients when considering high and low enoxaparin dose requirements. We hypothesize that creatinine clearance (CrCl) predicts goal enoxaparin dose better than weight-based dosing.
METHODS: A retrospective review was conducted on patients admitted to an urban, academic Level I trauma center from August 2017 to February 2020. Patients were included if greater than 18 years, admitted longer than 48 hours, and head and neck AIS ≥ 3. Patients were excluded if they did not have TBI, if they received deep vein thrombosis prophylaxis other than enoxaparin 12-hour dosing, if no anti-Xa levels were drawn, or if the goal anti-Xa level was not reached. Patients were grouped into dosing cohorts based on dose of enoxaparin required to reach goal. Pearson's correlation was used to compare mean CrCl and mean weight across dosing cohorts.
RESULTS: A total of 120 patients met inclusion and exclusion criteria, mean age was 47 years and 68% of patients were male. The mean hospital length of stay was 24 days. There were 5 (4.2%) deep vein thrombosis, no pulmonary embolism, and 5 (4.2%) patients died. Mean CrCl increased significantly with increased dosing of enoxaparin, Pearson's correlation coefficient of 0.484 ( p < 0.001). Weight on admission also increased with increasing enoxaparin dose requirements, with Pearson's correlation coefficient of 0.411 ( p < 0.001).
CONCLUSION: Creatine clearance predicts goal enoxaparin dose in TBI better than a weight-based dosing strategy. Further research with a larger patient population is required to validate CrCl values to guide enoxaparin dosing.
LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level IV.
参考来源
- Park G, Dhillon NK, Fierro NM, et al. Creatinine clearance predicts the goal enoxaparin dose in traumatic brain injury. J Trauma Acute Care Surg. 2023. PMID: 37335174. doi:10.1097/TA.0000000000004059
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。